Cytokinetics Inc FDA Advisory Committee for Omecamtiv Mecarbill Update Call Transcript
Good morning, and welcome, ladies and gentlemen, to Cytokinetics conference call to discuss the outcome of yesterday's FDA Advisory Committee Meeting for omecamtiv mecarbil. At this time, I would like to inform you that this call is being recorded (Operator Instructions)
I will now turn the call over to Diane Weiser, Cytokinetics Senior Vice President of Corporate Communications and Investor Relations. Please go ahead.
Good morning, and thanks for joining us on the call today. On the call with me today are Robert Blum, President and Chief Executive Officer, who will provide a summary of the Advisory Committee outcome and implications for the potential approval of omecamtiv mecarbil; as well as Fady Malik, EVP of Research and Development; Andrew Callos, EVP and Chief Commercial Officer; and Ching Jaw, SVP and Chief Financial Officer, who will all participate in our Q&A.
Please note that portions of the following discussion including our responses to questions, contains statements that relate
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |